Burixafor Hydrobromide
Tier C — Watch / tradeBurixafor Hydrobromide
Targets：CXCR4
Indications (approved)：Haematopoietic stem cell transplantation, Prostate cancer, Acute myeloid leukaemia, Multiple myeloma, Non-Hodgkin lymphoma, Hodgkin's disease
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| BURIX-008 | 917022-11-8 | N2-(((1r,4r)-4-(aminomethyl)cyclohexyl)methyl)-6-chloropyrimidine-2,4-diamine |
| BURIX-002 | 27687-14-5 | (1r,4r)-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexane-1-carboxylic acid |
| BURIX-003 | 749866-15-7 | tert-butyl (((1r,4r)-4-carbamoylcyclohexyl)methyl)carbamate |
| BURIX-004 | 473923-79-4 | tert-butyl (((1r,4r)-4-cyanocyclohexyl)methyl)carbamate |
| BURIX-005 | 166168-16-7 | tert-butyl (((1r,4r)-4-(aminomethyl)cyclohexyl)methyl)carbamate |
| BURIX-006 | 10132-07-7 | 2,6-dichloropyrimidin-4-amine |
| BURIX-007 | 917022-10-7 | tert-butyl (((1r,4r)-4-(((4-amino-6-chloropyrimidin-2-yl)amino)methyl)cyclohexyl)methyl)carbamate |
| BURIX-009 | 917021-59-1 | tert-butyl cyclohexyl(3-oxopropyl)carbamate |
| BURIX-010 | 917022-12-9 | tert-butyl (3-((((1r,4r)-4-(((4-amino-6-chloropyrimidin-2-yl)amino)methyl)cyclohexyl)methyl)amino)propyl)(cyclohexyl)carbamate |
| BURIX-011 | 917022-13-0 | tert-butyl (((1r,4r)-4-(((4-amino-6-chloropyrimidin-2-yl)amino)methyl)cyclohexyl)methyl)(3-((tert-butoxycarbonyl)(cyclohexyl)amino)propyl)carbamate |
| BURIX-012 | 917022-14-1 | tert-butyl (((1r,4r)-4-(((4-amino-6-(piperazin-1-yl)pyrimidin-2-yl)amino)methyl)cyclohexyl)methyl)(3-((tert-butoxycarbonyl)(cyclohexyl)amino)propyl)carbamate |
| BURIX-013 | 682-30-4 | diethyl vinylphosphonate |
| BURIX-014 | 1191450-18-6 | tert-butyl (((1r,4r)-4-(((4-amino-6-(4-(2-(diethoxyphosphoryl)ethyl)piperazin-1-yl)pyrimidin-2-yl)amino)methyl)cyclohexyl)methyl)(3-((tert-butoxycarbonyl)(cyclohexyl)amino)propyl)carbamate |
| Burixafor Hydrobromide | - | - |
| BURIX-001 | 1197-18-8 | (1r,4r)-4-(aminomethyl)cyclohexanecarboxylic acid |
Frequently asked questions
What are the approved indications of Burixafor Hydrobromide?
Approved indications include: Haematopoietic stem cell transplantation, Prostate cancer, Acute myeloid leukaemia, Multiple myeloma, Non-Hodgkin lymphoma, Hodgkin's disease.
When does the Burixafor Hydrobromide patent expire?
No public expiry year is available for Burixafor Hydrobromide yet; this page updates once verified.
How many synthesis routes are recorded for Burixafor Hydrobromide?
1 synthesis routes are recorded; the shortest is 11 steps with 190 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Burixafor Hydrobromide intermediates?
All intermediates in Burixafor Hydrobromide routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Burixafor Hydrobromide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21